Literature DB >> 2011135

Overview: genes that predispose to cancer.

A G Knudson1.   

Abstract

Heredity and environment both operate in the origin of cancer. Dominantly heritable cancer is caused by 'cancer' genes that impart high relative risks but account for only a small part of the incidence of cancer; they are usually recessive in oncogenesis, mutation or loss of the second allele being necessary. Non-hereditary forms of cancer may involve the same genes. Other genes interact with environment in carcinogenesis; these may impart relatively small relative risks, but because their frequencies may be high, the attributable risks can be great, as probably is the case with lung cancer. The process of carcinogenesis is thought to involve 2 or more somatic genetic events in most cases. The genes whose germline mutations cause dominantly inherited cancer can also be mutated somatically to cause non-hereditary cancer. Other genes may influence the numbers of target cells, or the proliferation of once-hit stem cells, without being critical events on the path to cancer. However, such genes could greatly influence the incidence of a cancer. Other genes, such as that for Bloom's syndrome, may affect the rates at which first and second events occur. Finally, other genes may influence the occurrence of events critical for progression and metastasis, such as vascularization of a small tumor.

Entities:  

Mesh:

Year:  1991        PMID: 2011135     DOI: 10.1016/0027-5107(91)90013-e

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

Review 1.  Mouse models in oncogenesis and cancer therapy.

Authors:  M V Céspedes; I Casanova; M Parreño; R Mangues
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

Review 2.  Molecular biology as a tool for the treatment of cancer.

Authors:  Carla de Castro Sant' Anna; Alberto Gomes Ferreira Junior; Paulo Soares; Fabricio Tuji; Eric Paschoal; Luiz Cláudio Chaves; Rommel Rodriguez Burbano
Journal:  Clin Exp Med       Date:  2018-07-13       Impact factor: 3.984

3.  An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

Authors:  L Worrillow; P Baskaran; M A Care; A Varghese; T Munir; P A Evans; S J O'Connor; A Rawstron; L Hazelwood; R M Tooze; P Hillmen; D J Newton
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

4.  Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis.

Authors:  Araika Gutiérrez-Rivera; Haizea Iribar; Anna Tuneu; Ander Izeta
Journal:  Stem Cells Int       Date:  2012-04-01       Impact factor: 5.443

5.  The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers.

Authors:  J A Hamilton; L M Stewart; L Ajayi; I C Gray; N E Gray; K G Roberts; G J Watson; A V Kaisary; D Snary
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

6.  Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer.

Authors:  Martina Kluth; Simon Jung; Omar Habib; Mina Eshagzaiy; Anna Heinl; Nina Amschler; Sawinee Masser; Malte Mader; Frederic Runte; Philipp Barow; Sohall Frogh; Jazan Omari; Christina Möller-Koop; Claudia Hube-Magg; Joachim Weischenfeldt; Jan Korbel; Stefan Steurer; Till Krech; Hartwig Huland; Markus Graefen; Sarah Minner; Guido Sauter; Thorsten Schlomm; Ronald Simon
Journal:  Oncotarget       Date:  2017-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.